Companies: 10,795·Total market cap: $144.5T
AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTXNASDAQHealthcare● Active
$3.85
+$0.03(+0.79%)
Market Cap$105497792
P/E Ratio—
52W High$6.91
52W Low$1
ForecastMarket CapPE Ratio

AN2 Therapeutics, Inc. (ANTX) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

antx · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 8 Wall Street analysts in the past 3 months

SellBuy

Buy

8 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
3
Sell
0
Strong Sell
0
Total: 8 · Buy rate: 62.5%

12-Month Price Target

High

$9.00

Consensus

$9.00

+133.8% upside

Low

$9.00

Median: $9 · Last Close: $3.85

The AN2 Therapeutics, Inc. (ANTX) analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month ANTX price target is $9.00, representing +133.8% upside from the current price of $3.85.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Analyst price target coverage is insufficient to generate a forecast chart for this stock.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$3.66↓ 5.00%

1-day model range: $3.63–$3.68. Peak: $3.68 (-5.00%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%36%64%
0Buy
5Neutral
9Sell
RSI (14)32.2Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · ANTX · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$4.02SELL
MA 10$4.25SELL
MA 20$4.43SELL
MA 50$4.09SELL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $ANTX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$4.01SELL
EMA 10$4.18SELL
EMA 20$4.30SELL
EMA 50$4.22SELL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $ANTX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Leerink Partners2026-05-14
Upgrade ↑
Market Perform→Outperform
JMP Securities2025-05-05
Maintains
Market Outperform→Market Outperform
Citizens Capital Markets2025-03-26
Maintains
Market Outperform→Market Outperform
Citizens Capital Markets2025-02-25
Maintains
Market Outperform→Market Outperform
JMP Securities2025-02-03
Maintains
Market Outperform→Market Outperform
JMP Securities2024-11-19
Maintains
Market Outperform→Market Outperform
TD Cowen2024-11-18
Downgrade ↓
Buy→Hold
JMP Securities2024-08-09
Maintains
Market Outperform→Market Outperform
Leerink Partners2024-07-03
Upgrade ↑
Market Perform→Outperform
Evercore ISI Group2024-05-16
Maintains
In Line→In Line

Wall Street analysts have recently issued updated ratings on AN2 Therapeutics, Inc. (ANTX) stock. Of the recent 21 rating actions, 3 were upgrades and 5 were downgrades. 8 analysts currently cover ANTX.

Analyst Recommendation Trends

Buy ratings1 → 1
Hold ratings0 → 0
Sell ratings0 → 0

ANTX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↓ 100.0% YoY

Revenue Next Year

$33M

EPS This Year

$-1.72

EPS Next Year

$-1.12

↓ 35.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ANTX EPS of $-1.72 for the current fiscal year, based on estimates from 2 analysts. The ANTX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ANTX stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ANTX price target is $9.00 (+133.8% upside), with an analyst consensus of Buy.

The ANTX short-term stock prediction for tomorrow is $3.66 (-5.00%).

AN2 Therapeutics, Inc. trades on NASDAQ under the ticker ANTX. The ANTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Related pages

EarningsRevenuePE RatioFinancialsMarket CapInsider TradesDividendsPrice History

Frequently asked questions

ANTX forecast · 8 questions

According to 8 Wall Street analysts, the average 12-month ANTX price target is $9.00, with a high forecast of $9.00 and a low of $9.00. The median price target is shown in the chart above when available. This implies +133.8% potential upside from the current price of $3.85.

ANTX price targetWhat is ANTX price targetANTX analyst price targetANTX 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.